

Haematologica  
HAEMATOL/2019/229252  
Version 4

Standardized monitoring of cytomegalovirus-specific immunity can improve risk stratification of recurrent cytomegalovirus reactivation after hematopoietic stem cell transplantation

Eva Wagner-Drouet, Daniel Teschner, Christine Wolschke, Dietlinde Janson, Kerstin Schäfer-Eckart, Johannes Gärtner, Stephan Mielke, Martin Schreder, Guido Kobbe, Mustafa Kondakci, Inken Hilgendorf, Marie von Lilienfeld-Toal, Stefan Klein, Daniela Heidenreich, Sebastian Kreil, Mareike Verbeek, Sandra Graß, Markus Ditschkowski, Tanja Gromke, Martina Koch, Monika Lindemann, Thomas Hünig, Traudel Schmidt, Anne Rasche, Harald Guldan, Sascha Barabas, Ludwig Deml, Ralf Wagner, and Daniel Wolff

Disclosures: 1. Funding: This study was supported in part by the German Federal Ministry of Education and Research (BMBF grant number 031A215) to Lophius Biosciences and by research funding from Lophius Biosciences to D.W., E.W., D.T., C.W., D.J., K.S-E., J.G., S.M., M.S., G.K., M.K., I.H., M.L-T., S.K., D.H., S.K., M.V., S.G., M.D., T.G., M.K., T.H., and M.L.. D.W. was supported by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation, grant number 324392634 - TRR 221). 2. Conflict of interest statement: The participating clinical and measurement centers (D.W., E.W., D.T., C.W., D.J., K.S-E., J.G., S.M., M.S., G.K., M.K., I.H., M.L-T., S.K., D.H., S.K., M.V., S.G., M.D., T.G., M.K., T.H., M.L.) received research funding from Lophius Biosciences for this study. L.D. is an employee, co-founder, Chief Scientific Officer and shareholder of Lophius Biosciences. S.B. is an employee and shareholder of Lophius Biosciences. T.S., H.G. and A.R. are employees of Lophius Biosciences. R.W. is Chairman of the Board and a shareholder of Lophius Biosciences. 3. Issued patents relevant to the T-Track® CMV assay used in this study: WO/2010/115984 "METHOD FOR POLYPEPTIDE TRANSFER INTO CELLS" WO/2003/080792 "USE OF UREA-ADJUVATED POLYPEPTIDES FOR DIAGNOSIS, PROPHYLAXIS AND TREATMENT" WO/2003/046212 "METHOD FOR IDENTIFYING TARGET EPITOPES OF THE T CELL MEDIATED IMMUNE RESPONSE AND FOR ASSAYING EPITOPE-SPECIFIC T CELLS"

Contributions: L.D., D.W., S.B. and R.W. contributed to the study conception and design; T.S., L.D., S.B. and R.W. organized, coordinated and supervised the study and its logistics; D.W., E.W., D.T., C.W., D.J., K.S-E., J.G., S.M., M.S., G.K., M.K., I.H., M.L-T., S.K., D.H., S.K., M.V., S.G., M.D. and T.G. acquired patient samples and contributed to data collection; E.W., T.H., M.K., M.L. and S.B. performed the ELISpot assays; S.B. and H.G. analyzed the ELISpot results; A.R., T.S., L.D. and R.W. conducted and supervised the interpretation of results; A.R. drafted the manuscript and figures; All authors contributed to, reviewed and approved the manuscript.